成人小说亚洲一区二区三区,亚洲国产精品一区二区三区,国产精品成人精品久久久,久久综合一区二区三区,精品无码av一区二区,国产一级a毛一级a看免费视频,欧洲uv免费在线区一二区,亚洲国产欧美中日韩成人综合视频,国产熟女一区二区三区五月婷小说,亚洲一区波多野结衣在线

立即打開
Swine flu fear a boost for Gilead

Swine flu fear a boost for Gilead

2009年05月04日

????The biotech's bottom line could benefit from sales of Tamiflu, one of the only treatments for the influenza strain.

????By Eugenia Levenson

????It's been a busy few weeks for Gilead Sciences.

????Since Fortune last checked in on it, the biotech has reported record first-quarter revenues, completed its all-cash acquisition of CV Therapeutics, and launched the Phase II trials of its most promising pipeline product, the four-in-one, once-daily HIV "quad pill."

????Now Gilead (GILD, Fortune 500) is in the spotlight again. As governments formulate their responses to the deadly swine flu outbreak, which has already claimed over 100 lives in Mexico and triggered a worldwide public health emergency, Gilead is one of the drugmakers that could benefit.

????That's because its antiviral pill Tamiflu, which is marketed by Roche, is one of two drugs that is effective against this strain of influenza. Gilead collects royalty payments from Tamiflu sales, which peaked at $2 billion in 2006 as countries rushed to stockpile the drug against the threat of avian flu.

????Tamiflu sales plummeted after governments finished building up their reserves. From 2007 to 2008, Gilead's royalties dropped 63% to $156 million, just 3% of annual revenues. But if countries are forced to dip into their stockpiles to combat the swine flu, sales could rebound.

????The U.S. Centers for Disease Control and Prevention has already released 12.5 million doses of Tamiflu, which Citigroup analyst Yaron Werber estimates are worth $250 million in sales. Confirmed cases of swine flu in the U.S. climbed to 91 Wednesday with the nation's first reported death, a 22-month old child who traveled to Houston from Mexico for treatment.

????"It remains to be seen how much usage there's going to be and how much further stockpiling there might be," says Werber. "But we assume that the U.S. government will need to restock that $250 million worth of orders. For every $100 million in sales, that adds roughly two cents to Gilead's bottom line."

????Other analysts are even more bullish. "Governments around the world, not just the U.S., that distribute Tamiflu are not going to take back the Tamiflu that's not used, so it's likely we'll see new purchases," says ThinkEquity's Jason Kolbert.

????Gilead shares have risen 4% since Friday to close at $47.60 Tuesday.

????Tamiflu - the tip of the iceberg

????Any boost from Tamiflu sales would be a bonus for Gilead, whose main growth continues to come from its first-in-class HIV-treatment franchise (which has helped the biotech make Fortune's list of Fastest-Growing Companies for three out of the past four years.)

????"When governments were stockpiling Tamiflu, one of the concerns among investors was that this was not a repeat business, and what would happen when those sales dried up," says Citi's Werber. "But because of the strength of their business in HIV, Gilead's been able to absorb that loss of royalties just fine and grow very robustly."

????Last week, the company reported record first-quarter revenues of $1.53 billion, up 22% from a year ago. Sales of Gilead's once-daily combination HIV drugs Atripla and Truvada drove the results, with revenues up 57% and 23%, respectively.

????Atripla and Truvada are already two of the most frequently prescribed HIV drugs. They include Gilead's proprietary compound tenofovir, which has become a preferred backbone treatment for HIV thanks to a superior efficacy and safety record.

????In fact, Gilead's drug portfolio stacks up so well against big pharma that when Pfizer (PFE, Fortune 500) and GlaxoSmithKline (GSK) recently announced plans to combine their HIV businesses into a new company, analysts largely dismissed the threat. "We see negligible impact as we believe [Gilead] clearly has the better drugs...and execution in HIV," Morgan Stanley's Sapna Srivastava wrote in a research note.

????Many analysts believe Gilead has emerged as the company best positioned to benefit as HIV care expands, driven by shifts towards aggressive screening and earlier treatment, or starting patients on antiviral therapy before a precipitous drop in T-cell count.

????If the Department of Health and Human Services revises its guidelines to recommend earlier treatment as anticipated, tens of thousands of new patients could begin therapy over the next few years. The majority would start on a regimen that included a Gilead drug.

????In the meantime, additional Tamiflu sales will only help Gilead's bottom line.

????"Tamiflu is very positive for Gilead because it comes in as a royalty payment, so there's very low overhead associated with that," says ThinkEquity's Kolbert. "The quality of these revenues is very, very high."

掃碼打開財(cái)富Plus App
无码免费一区二区三区| 美女扒开腿让男人桶爽揉| 国产亚洲精品福利在线无卡一| 国产精品永久免费,亚洲国产精品尤物YW在线观看| 国产日韩欧美精品一二三四| 人妻中文字幕无码在线a| 色综合天天综合婷婷伊人| 日韩精品中文字幕无码一区| 人人妻人人澡人人爽人人精品电影| 手机在线观看亚洲国产精品| 2024久热爱精品视频在线观看| 亚洲va国产日韩欧美精品色婷婷| 日韩a无码av一区二区三区| 亚洲A∨午夜成人片精品网站| 国产成人无码精品久久久露脸| 久久天天躁狠狠躁夜夜免费观看| 亚洲欧洲日产国码无码久久99| 日韩乱码人妻无码中文字幕| 久久麻豆精亚洲AV品国产| 精品人妻少妇一级毛片免费| 人妻无码AⅤ在线一区二区视频| 吃下面吃胸在线看无码| 久久久久久国产精品免费| 奇米影视7777久久精品free性欧美婬妇| 国内精品久久久久久久影视麻豆| 亚洲AV无码国产丝袜在线观看| 成人区精品一区二区婷婷| 99亚洲精品中文字幕无码不卡| 国产高清国内精品福利| 亚洲制服另类无码专区| 男人边做边吃奶头视频| 99精品国产在热久久无码| 国产欧美久久久精品影院| 精品无码中出一区二区| 亚洲AV永久无码精品网站| 亚洲日韩精品一区二区二三区四区| 国产AV无码专区亚洲A∨毛片| 少妇的肉体在线观看| 国产精品久久久久久久伊一| 国产日韩精品亚洲二区视频| 国产亚洲视频在线观看|